Freestone Grove Partners LP Regeneron Pharmaceuticals, Inc. Transaction History
Freestone Grove Partners LP
- $13.2 Trillion
- Q2 2025
A detailed history of Freestone Grove Partners LP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 43,411 shares of REGN stock, worth $24.7 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
43,411Holding current value
$24.7 Million% of portfolio
0.17%Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,420Shares Held
88.7MCall Options Held
1.98MPut Options Held
1.75M-
Vanguard Group Inc Valley Forge, PA9.42MShares$5.36 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.81 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$3.22 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.83MShares$2.75 Billion0.1% of portfolio
-
Dodge & Cox San Francisco, CA3.83MShares$2.18 Billion1.21% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $61B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...